No Data
No Data
KALA BIO Advances Eye Disease Therapies With New Funding
KALA BIO | 10-K: FY2024 Annual Report
KALA BIO Cash Resources of $51.2M as of Dec 31 Expected to Fund Ops Into 1Q 2026 >KALA
KALA BIO | 8-K: KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Press Release: KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
KALA BIO 4Q Loss/Shr $1.74 >KALA
kingrotch : thank you for your work


真名有晨 : Thank you very much
Please take care and rest.
iluvpoptarts : sry doc. I'm too busy counting the money your making me too look. muha
IamBadNewz : @Jaguar8 Been waiting (im)patiently for a pop on CGTX given the recent conference and news of insider buying but price hasn’t reacted. Your thoughts?
Jaguar8 OP IamBadNewz : You have to be patient
View more comments...